CLINICAL_TRIALS
research
· 2017-03-03
Clinical Trial Update: Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB [Phase 2, Phase 3]
Summary
A clinical trial update examining adjunctive recombinant human interleukin-2 therapy for multidrug-resistant tuberculosis across Phase 2 and Phase 3.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: MDR TB | Phase 2, Phase 3 | Status: UNKNOWN